Research guide
CJC-1295
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone (GHRH) that incorporates amino acid substitutions conferring resistance to dipeptidyl peptidase-4 (DPP-4) enzymatic degradation. This structural modification extends its half-life from minutes (natural GHRH) to 6-10 days, enabling less-frequent subcutaneous administration while maintaining physiological pulsatile growth hormone secretion patterns. CJC-1295 is available exclusively for research purposes through licensed compounding pharmacies or research suppliers and is not FDA-approved for therapeutic use.
What the research shows
CJC-1295 produces dose-dependent increases in growth hormone and IGF-1 secretion while preserving natural GH pulsatility (pulsatile secretion persists during continuous stimulation), unlike some non-physiological GH replacement approaches
Extended half-life of 6-10 days allows for once-weekly or twice-weekly administration schedules, resulting in more sustained and stable IGF-1 elevation compared to shorter-acting GH secretagogues
positive · Clinical pharmacology literature and research peptide analyses ↗
In animal models (GHRH knockout mice), once-daily CJC-1295 administration maintained normal body composition and growth, demonstrating clinical utility in subjects with intact pituitary GH secretory capability
CJC-1295 works synergistically with GHSR-1a agonists (e.g., Ipamorelin) through non-competing receptor pathways, producing superadditive GH secretion exceeding what either compound generates independently
positive · Research pharmacology literature and mechanism studies ↗
Short-term clinical trial data (up to 90 days continuous administration) shows no serious adverse events; the longest published study tracked 47 subjects for 13 weeks with transient injection-site reactions in 23 percent
positive · Clinical trial safety data literature ↗
No peer-reviewed human trial has evaluated CJC-1295 safety beyond 90 days of continuous administration; long-term studies are lacking and further research is needed to confirm safety profile
neutral · Safety review literature and clinical evidence summary ↗
CJC-1295's extremely long half-life (6-10 days) means it lacks a natural off-switch and may potentially cause unwanted side effects during long-term administration; theoretical long-term risks including glucose metabolism effects, cancer cell proliferation, or organ hypertrophy remain clinically uncharacterized
What experts say — both sides
CJC-1295 represents a more physiologically sound approach to GH axis stimulation compared to non-peptide secretagogues because it preserves natural pulsatile secretion patterns. The mechanism of action—working through the native GHRH receptor—suggests fewer off-target metabolic complications. However, the absence of any human trial beyond 90 days of continuous administration, combined with the compound's extremely long half-life creating an inherent lack of off-switch, represents a critical knowledge gap that prevents definitive safety assessment.
Peer-reviewed clinical pharmacology literature and research summaries ↗
CJC-1295 entered Phase 2 clinical trials for HIV-related lipodystrophy but was discontinued by the sponsoring company without completion of Phase 3 requirements. It has never completed the full clinical trial pathway required for FDA approval and remains an investigational compound. Recent FDA regulatory actions (2023-2026) have created an uncertain classification landscape: CJC-1295 was initially prohibited from compounding (October 2023, Category 2 status), then removed from Category 2 in April 2026 without placement on Category 1, leaving it in regulatory limbo pending Pharmacy Compounding Advisory Committee review.
CJC-1295 research suggests potential benefits in lean body mass, muscle protein synthesis, improved metabolic efficiency, and enhanced cellular repair mechanisms through restoration of youthful GH/IGF-1 axis function. The combination with selective GHSR agonists like Ipamorelin appears particularly promising given complementary mechanisms. However, most clinical evidence supporting these applications comes from short-duration studies, animal models, or mechanism-of-action research rather than long-term efficacy trials in target populations.
Safety & legal status
CJC-1295 is NOT FDA-approved for any therapeutic indication as of June 2026. The compound underwent Phase 2 clinical development by Amarantus Bioscience for HIV-related lipodystrophy but the sponsoring company discontinued development before completion of Phase 3 trials. CJC-1295 exists in a complex regulatory landscape: it was classified as a Category 2 bulk drug substance (prohibited from licensed pharmacy compounding) in October 2023, but this classification was removed on April 15, 2026, placing CJC-1295 in a regulatory gap pending Pharmacy Compounding Advisory Committee (PCAC) review with no current formal FDA classification. When prescribed by a licensed medical provider, CJC-1295 may be compounded by licensed 503B outsourcing facilities. Short-term safety profile: Human clinical trials through 90 days show no serious adverse events reported; transient injection-site reactions (mild erythema, swelling) occurred in approximately 23 percent of subjects in longer trials. Long-term safety: No human data exist beyond 13 weeks of continuous administration. Theoretical long-term concerns include potential effects on glucose metabolism, cancer cell proliferation (via sustained IGF-1 elevation), and organ hypertrophy, all uncharacterized due to absence of extended-duration trials. The extended half-life (6-10 days) creates clinical concern due to lack of rapid off-switch for adverse effects. All research-use CJC-1295 must be labeled "For Research Use Only" and cannot be marketed for human consumption without a valid physician prescription and compounding by a licensed facility.
Research use only. Nothing here is medical or dosing advice.
CJC-1295 — FAQ
What is the difference between CJC-1295 and CJC-1295 DAC?
CJC-1295 without DAC (Drug Affinity Complex) has a shorter half-life of 2-3 hours. CJC-1295 with DAC uses covalent albumin binding to extend the half-life to 6-10 days, allowing less-frequent dosing. The DAC version (albumin-bound) is more commonly referenced in research literature and allows for once-weekly or twice-weekly subcutaneous administration.
Can you stack CJC-1295 with other peptides?
Yes, CJC-1295 is frequently combined with Ipamorelin (a GHSR-1a agonist) in research settings. These peptides work through non-competing receptor pathways on the same somatotroph cell, producing synergistic or superadditive GH secretion exceeding either peptide alone. The combination is studied for enhanced GH output and metabolic effects.
How often is CJC-1295 injected?
Standard research protocols employ once-weekly or twice-weekly subcutaneous injection, depending on the extended half-life (6-10 days) and desired IGF-1 steady-state levels. Some protocols use twice-weekly dosing for more frequent stimulation, while others use once-weekly dosing for convenience.
Is CJC-1295 legal in 2026?
CJC-1295's legal status is uncertain as of June 2026. It was removed from FDA Category 2 bulk drug substances in April 2026 but was not reclassified to Category 1, leaving it in regulatory limbo. Licensed compounding pharmacies may legally prepare it when prescribed by a licensed provider, but this depends on pending PCAC review. It is not legal to purchase or use without a valid physician prescription.
What are the main side effects of CJC-1295?
Short-term side effects are minimal and primarily limited to injection-site reactions (redness, swelling, mild pain) in ~23 percent of subjects. Theoretical long-term concerns include potential effects on glucose metabolism, sustained IGF-1 elevation effects, and hypothetical organ hypertrophy, but these have not been observed or characterized in human trials due to lack of long-term data beyond 13 weeks of continuous administration.
See which vendors pass our audit for CJC-1295.
Why trust this comparison
- Every vendor is scored from real evidence on four public, weighted axes — before we know any margins.
- Purity claims are cross-checked against named third-party labs (MZ Biolabs, Finnrick, Janoshik). Claim-only purity is marked as such.
- The scoring code can't read which vendor pays us — the editorial-commerce firewall is enforced in software.
- We disclose the 20% / 10% Alpha Pro commission on every page, above the first link.
Vendors out-rank our own partner: Peptide Partners (9.0) and Protide Health (8.9) and Ascension Peptides (8.8) both score above Alpha Pro (8.6). We left it that way.